Brought to you by 
Rare disease start-up Bio Blast Pharma completes $32.7mm US IPO
29 Oct 2014
Executive Summary
Bio Blast Pharma Ltd., an Israeli start-up focused on rare and ultra-rare genetic diseases, completed its initial public offering in the US. The company netted $32.7mm through the sale of 3.2mm ordinary shares at $11. Bio Blast is the sixth Israeli firm to price a US IPO thus far in 2014, in addition to Lumenis, MediWound, Galmed, Vascular Biogenics, and Macrocure.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Rare disease start-up Bio Blast Pharma completes $32.7mm US IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice